The relationship between the eye and psoriasis has been recognized for decades, but the precise eye manifestations in patients with psoriasis and psoriatic arthritis are only recently coming to light. Psoriatic eye findings may include conjunctivitis, dry eye, episcleritis, and uveitis, all of which may precede articular changes. Uveitis, seen in 7% to 25% of psoriatic arthritis patients, may be recognized by the presence of conjunctival injection, photophobia, pain, lid swelling, or otherwise unexplained visual changes. Early recognition is paramount because its natural course may lead to vision loss. Immunopathogenesis has shown evidence for T-helper cell (Th) type 1 (Th1) and Th17 involvement in the pathogenesis of uveitis according to the murine experimental autoimmune uveitis model. Corticosteroids are the primary treatment modality; however, increasing emphasis has been placed on immunomodulators and biologics for more intractable cases. Referral to an ophthalmologist is essential for definitive diagnosis and treatment.
VrabecF.Histologic description of a case of psoriasis with conjunctival, corneal and cutaneous localization. Ophthalmologica.1952; 124(2): 105–8.
2.
SandvigK., WesterbergP.Ocular findings in psoriatics. Acta Ophthalmol (Copenh).1955; 33(4): 463–7.
3.
KnoxD.L.Psoriasis and intraocular inflammation. Trans Am Ophthalmol Soc.1979; 77: 210–24.
4.
KammerG.M., SoterN.A., GibsonD.J., SchurP.H.Psoriatic arthritis: a clinical, immunologic and HLA study of 100 patients. Semin Arthritis Rheum.1979; 9(2): 75–97.
5.
LambertJ.R., WrightV.Eye inflammation in psoriatic arthritis. Ann Rheum Dis, 1976; 35(4): 354–6.
6.
TwiltM., Swart van den BergJ.C., van MeursR., ten CateR., Van Suijlekom-SmitL.W.Persisting uveitis antedating psoriasis in two boys. Eur J Pediatr.2003; 162(9): 607–9.
7.
HantzchelH., OttoW., RomhildN.Characteristics of the early phase of ankylosing spondylitis. Z Gesamte Inn Med.1981; 36(6): 189–92.
8.
AmorB., SantosR.S., NahalR., ListratV., DougadosM.Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol.1994; 21(10): 1883–7.
9.
Bloch-MichelE., NussenblattR.B.International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol.1987; 103(2): 234–5.
10.
JabsD.A., NussenblattR.B., RosenbaumJ.T.Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol.2005; 140(3): 509–16.
11.
ZeboulonN., DougadosM., GossecL.Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis.2008; 67(7): 955–9.
12.
Catsarou-CatsariA., KatsambasA., TheodoropoulosP., StratigosJ.Ophthalmological manifestations in patients with psoriasis. Acta Derm Venereol.1984; 64(6): 557–9.
13.
PaivaE.S., MacalusoD.C., EdwardsA., RosenbaumJ.T.Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis.2000; 59(1): 67–70.
Said-NahalR., Miceli-RichardC., BerthelotJ.M.The familial form of spondylarthropathy: a clinical study of 115 multiplex families: Groupe Francais d'Etude Genetique des Spondylarthropathies. Arthritis Rheum.2000; 43(6): 1356–65.
Sampaio-BarrosP.D., CostallatL.T., BertoloM.B., NetoJ.F., SamaraA.M.Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol.2000; 29(3): 160–2.
18.
QueiroR., TorreJ., BelzumeguiJ.Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum.2002; 31(4): 264–70.
19.
ZameckiK.J., JabsD.A.HLA typing in uveitis: use and misuse. Am J Ophthalmol.149(2): 189–193, e2.
20.
KhanM.A., MathieuA., SorrentinoR., AkkocN.The pathogenetic role of HLA-B27 and its subtypes. Autoimmun Rev.2007; 6(3): 183–9.
21.
ThygesonP.Ocular manifestations of the dermatoses. Trans Am Acad Ophthalmol Otolaryngol.1952; 56(5): 737–50.
22.
HatchomeN., TagamiH.Hypopyon-iridocyclitis as a complication of pustular psoriasis. J Am Acad Dermatol.1985; 13(5 Pt 1): 828–9.
23.
GranJ.T., HusbyG.HLA-B27 and spondyloarthropathy: value for early diagnosis?J Med Genet.1995; 32(7): 497–501.
24.
OkamotoF., UmebayasiY., OhtsukaF., HommuraS.Factors associated with increased aqueous flare in psoriasis. Jpn J Ophthalmol.2001; 45(2): 172–6.
25.
BanaresA., Hernandez-GarciaC., Gernandez-GuitierrezB., JoverJ.A.Eye involvement in the spondyloarthropathies. Rheum Dis Clin North Am.1998; 24(4): 771–84, ix.
26.
ShermanM.S.Psoriatic arthritis; observations on the clinical, roentgenographic, and pathological changes. J Bone Joint Surg Am.1952; 34A (4): 831–52.
27.
ReedW.B., BeckerS.W.Psoriasis and arthritis. Arch Dermatol.1960; 81: 577–85.
28.
MainiR., O'SullivanJ., ReddyA., WatsonS., EdelstenC.The risk of complications of uveitis in a district hospital cohort. Br J Ophthalmol.2004; 88(4): 512–7.
BaldassanoVFJr.Ocular manifestations of rheumatic diseases. Curr Opin Ophthalmol1998; 9(6): 85–8.
33.
WirbelauerC.Management of the red eye for the primary care physician. Am J Med.2006; 119(4): 302–6.
34.
ZenginN., TolH., BaleviS., GunduzK., OkudanS., EndogruH.Tear film and meibomian gland functions in psoriasis. Acta Ophthalmol Scand.1996; 74(4): 358–60.
35.
ErbagciI., ErbagciZ., GungorK., BekirN.Ocular anterior segment pathologies and tear film changes in patients with psoriasis vulgaris. Acta Med Okayama.2003; 57(6): 299–303.
36.
GudmundsenK.J., O'DonnellB.F., PowellF.C.Schirmer testing for dry eyes in patients with rosacea. J Am Acad Dermatol.1992; 26(2 Pt 1): 211–4.
37.
KarabulutA.A., YalvacI.S., VahabogluH., NurozlerA.B., DumanS.Conjunctival impression cytology and tear-film changes in patients with psoriasis. Cornea.1999; 18(5): 544–8.
38.
van LaarJ.A., van HagenP.M.Cytokines in uveitis. Clin Med Res.2006; 4(4): 248–9.
39.
PowerW.J., RodriguezA., Pedroza-SeresM., FosterC.S.Outcomes in anterior uveitis associated with the HL A-B27 haplotype. Ophthalmology.1998; 105(9): 1646–51.
40.
GladmanD.D.Clinical aspects of the spondyloarthropathies. Am J Med Sci.1998; 316(4): 234–8.
41.
ZhuJ., PaulW.E.Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev.238(1): 247–62.
42.
RomagnaniS.Biology of human TH1 and TH2 cells. J Clin Immunol.1995; 15(3): 121–9.
43.
WeaverC.T., HarringtonL.E., ManganP.R., GavrieliM., MurphyK.M.Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity.2006; 24(6): 677–88.
44.
NogralesK.E., ZabaL.C., Guttman-YasskyE.Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol.2008; 159(5): 1092–102.
45.
KryczekI., BruceA.T., GudjonssonJ.E.Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol.2008; 181(7): 4733–41.
46.
BettelliE., KornT., KuchrooV.K.Th17: the third member of the effector T cell trilogy. Curr Opin Immunol, 2007; 19(6): 652–7.
47.
OuyangW., KollsJ.K., ZhengY.The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity.2008; 28(4): 454–67.
48.
KagamiS., RizzoH.L., LeeJ.J., KoguchiK., BlauveltA.Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol.130(5): 1373–83.
49.
PartschG., SteinerG., LeebB.F., DunkyA., BrollH., SmolenJ.S.Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol.1997; 24(3): 518–23.
GriffithsC.E., StroberB.E., van de KerkhofP.Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med.362(2): 118–28.
52.
GottliebA.B., AntoniC.E.Treating psoriatic arthritis: how effective are TNF antagonists?Arthritis Res Ther.2004; 6(suppl 2): S31–5.
53.
VictorF.C., GottliebA.B., MenterA.Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol.2003; 21(5): 392–7.
54.
NakamuraS., YamakawaT., SugitaM.The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci.1994; 35(11): 3884–9.
55.
SartaniG., SilverP.B., RizzoL.V.Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol V is Sci.1996; 37(11): 2211–8.
56.
CaspiR.R., RobergeF.G., McAllisterC.G.T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol.1986; 136(3): 928–33.
57.
BritoB.E., O'RourkeL.M., PanY., AnglinJ., PlanckS.R., RosenbaumJ.T.IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci.1999; 40(11): 2583–9.
58.
FoxmanE.F., ZhangM., HurstS.D.Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J Immunol.2002; 168(5): 2483–92.
59.
KulkarniP.S., SrinivasinB.D.Cachectin: a novel polypeptide induces uveitis in the rabbit eye. Exp Eye Res.1988; 46(4): 631–3.
60.
RosenbaumJ.T., HowesE.L.Jr., RubinR.M., SamplesJ.R.Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol.1988; 133(1): 47–53.
61.
FleisherL.N., FerrellJ.B., McGahanM.C.Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin. Inflammation.1990; 14(3): 325–35.
62.
RobertsonM., LiversidgeJ., ForresterJ.V., DickA.D.Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci.2003; 44(7): 3034–41.
63.
GreinerK., MurphyC.C., WillermainF.Anti-TNF alpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci.2004; 45(1): 170–6.
64.
McPhersonS.W., RobertsJ.P., GregersonD.S.Systemic expression of rat soluble retinal antigen induces resistance to experimental autoimmune uveoretinitis. J Immunol.1999; 163(8): 4269–76.
65.
SinghV.K., RaiG., AgarwalS.S.Role of cytokines in experimental and clinical uveitis. Indian J Ophthalmol.2001; 49(2): 81–90.
66.
CaspiR.R.A look at autoimmunity and inflammation in the eye. J Clin Invest.2010; 120(9): 3073–83.
67.
LugerD., SilverP.B., TangJ.Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med.2008; 205(4): 799–810.
68.
CaspiR.R., ChanC.C., GrubbsP.B.Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice. J Immunol.1994; 152(2): 890–9.
69.
TangJ., ZhuW., SilverP.B., SuS.B., ChanC.C., CaspiR.R.Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: initial encounter with autoantigen defines disease phenotype. J Immunol.2007; 178(9): 5578–87.
70.
DamskerJ.M., HansenA.M., CaspiR.R.Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci.2010; 1183: 211–21.
71.
RosenbaumJ.T., SmithJ.R.Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol.2002; 20(6 suppl 28): S143–5.
72.
HaleS., LightmanS.Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine.2006; 33(4): 231–7.
73.
Loteprednol Etabonate US Uveitis Study (LEUUS) Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol.1999; 127(5): 537–44.
74.
MohammadD.A., SweetB.V., ElnerS.G.Retisert: is the new advance in treatment of uveitis a good one?Ann Pharmacother.2007; 41(3): 449–54.
75.
JaffeG.J., McCallumR.M., BranchaudB., SkalakC., ButunerZ., AshtonP.Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology.2005; 112(7): 1192–8.
76.
GalorA., JabsD.A., LederH.A.Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology.2008; 115(10): 1826–32.
77.
BakerH., RyanT.J.Generalized pustular psoriasis: a clinical and epidemiological study of 104 cases. Br J Dermatol.1968; 80(12): 771–93.
78.
JabsD.A., RosenbaumJ.T., FosterC.S.Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol.2000; 130(4): 492–513.
79.
Diaz-LlopisM., Garcia-DelpechS., SalomD.Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther.2008; 24(3): 351–61.
80.
SuhlerE.B., SmithJ.R., GilesT.R.Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol.2009; 127(6): 819–22.
81.
LindstedtE.W., BaarsmaG.S., KuijpersR.W., van HagenP.M.Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol.2005; 89(5): 533–6.
82.
Benitez-del-CastilloJ.M., Martinez-de-la-CasaJ.M., Pato-CourE.Long-term treatment of refractory posterior uveitis with anti-TNF alpha (infliximab). Eye (Lond).2005; 19(8): 841–5.
83.
GottliebA.B., MathesonR.T., LoweN.A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol.2003; 139(12): 1627–32.
84.
ChaudhariU., RomanoP., MulcahyL.D., DooleyL.T., BakerD.G., GottliebA.B.Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet.2001; 357(9271): 1842–7.
85.
MenterA., TyringS.K., GordonK.Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol.2008; 58(1): 106–15.
86.
MeaseP.J., KivitzA J., BurchF.X.Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum.2004; 50(7): 2264–72.
87.
AntoniC.E., KavanaughA., KirkhamB.Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum.2005; 52(4): 1227–36.
88.
MeaseP.J., OryP., SharpJ.T.Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis.2009; 68(5): 702–9.
89.
GordonK.B., LangleyR.G., LeonardiC.Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol.2006; 55(4): 598–606.
BraunJ., BaraliakosX., ListingJ., SieperJ.Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum.2005; 52(8): 2447–51.
92.
RudwaleitM., RodevandE., HolckP.Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis.2009; 68(5): 696–701.
FosterC.S., TufailF., WaheedN.K.Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol.2003; 121(4): 437–40.
97.
GuignardS., GossecL., SalliotC.Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis.2006; 65(12): 1631–4.
98.
GalorA., PerezV.L., HammelJ.P., LowderC.Y.Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology.2006; 113(12): 2317–23.
99.
Cobo-IbanezT., del Carmen OrdonezM., Munoz-FernandezS., Madero-PradoR., Martin-MolaE.Do TNF-blockers reduce or induce uveitis?Rheumatology (Oxford).2008; 47(5): 731–2.
100.
KakkasseryV., MerglerS., PleyerU.Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res.2010; 35(8): 751–6.
101.
SimoniniG., TaddioA., CattaliniM.Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken).2011; 63(4): 612–8.
102.
TheodossiadisP.G., MarkomichelakisN.N., SfikakisP.P.Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina.2007; 27(4): 399–413.
TabanM., DuppsW.J., MandellB., PerezV.L.Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm.2006; 14(3): 145–50.
106.
MonnetD., MoachonL., DougadosM., BrezinA.P.Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol.2006; 2(7): 393–7.
107.
Kaipiainen-SeppanenO., LeinoM.Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis.2003; 62(1): 88–9.
108.
LimL.L., FraunfelderF.W., RosenbaumJ.T.Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum.2007; 56(10): 3248–52.
